$JNJ news
The latest JNJ stock news: headlines, filings, AI summaries and sentiment for $JNJ, updated around the clock.
- Ascendis Pharma Reports Q3 Revenue Growth of 90.7% Year-over-Year
- Legend Biotech Reports Q3 2026 Profitability Driven by CARVYKTI Global Expansion
- Johnson & Johnson's Caplyta Meets Primary Endpoints in Bipolar Mania Clinical Trial
- US Markets Recover from Post-Election Slump Amid Positive Clinical Trial Data for Eli Lilly and Johnson & Johnson
- Johnson & Johnson Venture Fund Participates in $100 Million Financing Round for Delix Therapeutics
- Johnson & Johnson Experimental Immunotherapy Combination Reduces Prostate Cancer PSA Levels in Early Trial
- Intuitive Surgical Q3 2026 Performance: Analyzing Robot Placements and Recurring Revenue Growth
- Johnson & Johnson Announces Positive Late-Stage Trial Results for Psoriatic Arthritis Treatment
- Anika Therapeutics Reports Q3 2026 Revenue Growth and Improved Profitability
- Genmab Reports Strong Q3 2026 Growth Driven by DARZALEX and EPKINLY Sales
- Pomerantz Law Firm Investigates Johnson & Johnson Following Q3 2026 Financial Results
- Kimberly-Clark Shares Rise Following Better-Than-Expected Third Quarter Results
- Genmab Shares Double Following Three Successful Phase 3 Cancer Drug Trials
- Kimberly-Clark Completes $48.7 Billion Acquisition of Kenvue
- Kimberly-Clark Completes $49 Billion Acquisition of Kenvue
- Securitize Expands Onchain U.S. Equity Offering to 25 Stocks via Solana
- Johnson & Johnson Reports 94% Success Rate in Clinical Trial for Shockwave Javelin Catheter
- Johnson & Johnson Reports Lower Mortality Rates for Impella Heart Pump Support
- Johnson & Johnson Raises Full-Year Guidance Despite $7 Billion Litigation and Acquisition Charges
- Pomerantz Law Firm Investigates Johnson & Johnson Following Q3 2026 Earnings Miss
- Alexandria Real Estate Equities Celebrates 20 Years of Prix Galien USA Partnership
- Johnson & Johnson Reports Q3 Revenue Growth Amid MedTech Weakness and Future Earnings Dilution Risks
- Johnson & Johnson Reports Positive Prostate Cancer Drug Trial Results While Microsoft Announces Employee Buyouts
- Johnson & Johnson Reports 75% Tumor Response Rate in Early-Stage Prostate Cancer Trial
- JOHNSON & JOHNSON - 10-Q Filing
- AI Infrastructure and Apple iPhone Duo Demand Drive Market Rebound
- Moderna's mRNA Pipeline Expansion Drives Growth Potential Beyond COVID-19 Vaccines
- Jim Cramer's Key Market Observations and Stock Movements for October 20
- Healthcare Sector Performance and Key Stock Movements for the Week
- Johnson & Johnson Reports Strong Q3 Results Despite Medtech Challenges
- Johnson & Johnson Raises Full-Year Sales Outlook Despite Medical Device Concerns
- Johnson & Johnson Raises Full-Year Sales Outlook Amid Strong Pharmaceutical Growth
- Johnson & Johnson Reports Q3 2026 Earnings with Mixed Performance Across Segments
- Meta Shares Rise for Second Consecutive Day Amid Positive Reception of New AI Model Family
- Markets Edge Lower as Earnings Season Begins
- Johnson & Johnson Q3 Earnings Affected by Talc Litigation Settlement, MedTech Slows Growth
- Johnson & Johnson Shares Drop on Mixed Earnings Despite Strong Pharmaceutical Performance
- Johnson & Johnson Considering Spin-Off of Hips-and-Knees Business
- Johnson & Johnson Reports Earnings Beat but GAAP Profit Plummets, Sending Stock Down
- Bank Earnings and Semiconductor Pressure Drive Mixed Market Performance
- Stocks Making Significant Moves Midday: Apple, Meta Platforms, Bumble, and More
- Johnson & Johnson Shares Decline Despite Raised Guidance Amid Disappointing MedTech Revenues
- Key Market Watchpoints: Chip Stocks Continue Decline Amid Earnings Reports and AI Sector Volatility
- JOHNSON & JOHNSON - 8-K Filing
- Premarket Stock Movements: JPMorgan Chase, Micron, UnitedHealth and Others React
- Johnson & Johnson: Innovative Medicine Growth Offsets Stelara Decline
- Johnson & Johnson Reports Strong Earnings Amid Geopolitical Challenges
- Johnson & Johnson Shares Decline Premarket Despite Raised Earnings Guidance
- Johnson & Johnson Announces Quarterly Dividend of $1.34 Per Share
- Johnson & Johnson Exceeds Q3 Earnings Expectations and Raises Full-Year Guidance